Form 4: Enveric Biosciences Director Michael Webb Receives Restricted Stock Grant

Director Michael Webb of Enveric Biosciences, Inc. reports the acquisition of 47,733 shares of common stock through a restricted stock grant.

Summary

• Michael Webb, a director of Enveric Biosciences, Inc., filed a Form 4 on October 11, 2024.
• The report details a transaction on October 9, 2024, where Webb acquired 47,733 shares of Enveric Biosciences common stock.
• These shares were granted as restricted stock under the company's 2020 Long-Term Incentive Plan, as amended.
• The restricted stock will vest in full on December 31, 2024, contingent upon the terms of the plan and Webb's award agreement.

Sentiment

Score: 7

Explanation: The document reflects a standard transaction of granting restricted stock to a director, which is generally viewed as a positive sign of aligning management interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of restricted stock aligns the director's interests with the long-term performance of Enveric Biosciences.
• The vesting schedule encourages continued service and contribution from the director until December 31, 2024.

Future Outlook

The vesting of the restricted stock on December 31, 2024, is contingent upon the terms and conditions of the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan and the reporting person's restricted stock award agreement.

Industry Context

Stock grants to directors are a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock grants to directors are a common practice across the biotechnology industry.
• Companies like Amgen, Biogen, and Gilead Sciences also utilize stock grants as part of their compensation packages for directors and executives.
• The size of the grant is typical for a director-level position in a company of Enveric Biosciences' size and stage of development.

Stakeholder Impact

• The stock grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Enveric Biosciences, Michael Webb, restricted stock, Form 4, beneficial ownership, incentive plan, ENVB, director